Close Menu

NEW YORK – Oncocyte said Thursday that it has entered a distribution agreement with CORE Diagnostics to expand the commercial availability of its DetermaRx test to India, the Middle East, and Africa.

DetermaRx is Oncocyte’s first commercially launched assay and was initially called the Razor Genomic test when Oncocyte acquired Razor and it's IP last year.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.